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MiceChemical or electrical stimulation of the dorsal portion of the midbrain periaqueductal gray (dPAG) produces
anxiogenic and antinociceptive effects. In rats, chemical stimulation of dPAG by local infusion of the
neuropeptide corticotropin-releasing factor (CRF) provokes anxiogenic effects in the elevated plus-maze test
(EPM). CRF also produces antinociception when injected intracerebroventricularly in rats, however it remains
unclear whether this response is also observed following CRF injection into the dPAG in mice. Yet, given that
there are CRF1 and CRF2 receptor subtypes within the PAG, it is important to show in which receptor subtypes
CRF exert its anxiogenic and antinociceptive effects in the dPAG. Here, we investigated the role of these
receptors in the anxiogenic (assessed in the EPM) and antinociceptive (assessed by the Formalin test: 2.5%
formalin injection into the right hind paw) effects following intra-dPAG infusion of CRF in mice. The results
show that intra-dPAG injections of CRF (75 pmol/0.1 μl and 150 pmol/0.2 μl) produced dose-dependent
anxiogenic and antinociceptive effects. In addition, local infusion of NBI 27914 (5-chloro-4-(N-(cyclopropyl)
methyl-N-propylamino)-2-methyl-6-(2,4,6-trichlorophenyl)-aminopyridine; 2 nmol/0.2 μl), a CRF1 receptor
antagonist, completely blocked both the anxiogenic and antinociceptive effects induced by local infusion of
CRF, while that of antisauvagine 30 (ASV30; 1 nmol/0.2 μl), a CRF2 receptor antagonist, did not alter the CRF
effects. Present results are suggestive that CRF1 (but not CRF2) receptors play a crucial role in the anxiogenic
and antinociceptive effects induced by CRF in the dPAG in mice.ade de Ciências Farmacêuticas,
-902, Araraquara, SP, Brazil.
uza@pq.cnpq.br
evier OA license.© 2011 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
The dorsal periaqueductal gray matter (dPAG) is a midbrain site
markedly involved in fear/anxiety-evoked responses as well as in
nociception (see, for example, Bandler and Carrive, 1988; Deakin and
Graeff, 1991; Fardin et al., 1984a,b; Litvin et al., 2007). Chemical or
electrical stimulation of dPAG elicits defensive behavior such as
freezing, ﬂight and ﬁght reaction, escalation of risk assessment
behavior and arousal (e.g., Bandler and Carrive, 1988; Schenberg
et al., 2005) and autonomic activation (e.g., tachycardia, hypertension,
tachypnea — Bandler et al., 1991; Hayward et al., 2003; McDougall
et al., 1985). These responses are generally accompanied by
antinociception (e.g., Coimbra and Brandão, 1997; Fanselow, 1991).
Among the various neurotransmitter systems pointed out to play a
role in the mediation of defensive and antinociceptive responseselicited by environmentally aversive stimuli, the neuropeptide
corticotropin-releasing factor or hormone (CRF or CRH) has attracted
the interest of many researchers investigating its role in the
modulation of defensive reactions (Baldwin et al., 1991; Berridge
and Dunn, 1989; Carvalho-Netto et al., 2007; Litvin et al., 2007;
Stenzel-Poore et al., 1994). CRF is a 41-amino acid peptide that
activates the hypothalamo–pituitary–adrenal (HPA) axis, releasing, at
the end of a cascade, glucocorticoids from the adrenal gland. HPA axis
hyperactivation has been related to several brain disturbances such as
anxiety disorders, depression, epilepsy and drug addiction (Allen
et al., 2011; Kanner, 2011; Lim et al., 2011; Pariante and Lightman,
2008). Besides its action on the HPA axis, CRF also acts in other brain
areas such as the amygdala (Carrasco and Van de Kar, 2003; Shekhar
et al., 2005), bed nucleus of stria terminalis (Sahuque et al., 2006),
locus coeruleus (Chen et al., 1992), dorsal raphe nucleus (Carrasco
and Van de Kar, 2003) and PAG (Borelli and Brandão, 2008; Martins
et al., 1997) increasing anxiety-like responses in various animal tests.
Regarding the involvement of CRF receptors located within the
PAG on fear/anxiety-related responses, previous studies have shown
that intra-dPAG infusion of h/rCRF (Martins et al., 2000) and ovine
CRF (Borelli and Brandão, 2008) increase anxiety-like behaviors in
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test of anxiety (Handley and Mithani, 1984; Lister, 1987; Pellow et al.,
1985). In mice, Carvalho-Netto et al. (2007) have shown that intra-
PAG infusion of ovine CRF increases avoidance behavior in two
different anxiety tests, themouse defense test battery (MDTB) and the
rat exposure test (RET).
It has been emphasized that CRF can activate Gs-protein-coupled
CRF1 or CRF2 receptors triggering the cAMP-PKA cascade pathway
(Chang et al., 1993; Chen et al., 1993; Lovenberg et al., 1995; Perrin
et al., 1995; Vita et al., 1993). Moreover, both receptor subtypes have
been found strongly expressed in different PAG columns, where a high
density of CRFergic neurons have also been reported (Merchenthaler,
1984; Steckler and Holsboer, 1999; Swanson et al., 1983). In addition,
Bowers et al. (2003) have related CRF microinjection into the PAG
with increased neuron ﬁring and excitatory activity. However, it
remains unclear at which receptor subtypes (CRF1, CRF2 or both) CRF
produces anxiety-like responses in rodents. Evidence showing that
CRF1 receptors play an important role in the modulation of defensive
responses has been reported in several studies. For instance, intra-
PAG (Litvin et al., 2007) or intracerebroventricular (Tezval et al.,
2004) infusions of CRF1 receptor agonist, cortagine, produce anxio-
genic-like effects in various animal tests of anxiety. On the other
hand, intracerebral injection of CRF2 receptor antagonist (e.g.,
antisauvagine-30) has been related to both anxiogenic and anxiolytic
effects (Kishimoto et al., 2000; Takahashi et al., 2001). However, as far
as we know there are no studies comparing the anxiogenic effects of
CRF at CRF1 and CRF2 receptors within the PAG.
Different types of environmentally induced antinociception have
been reported in a wide range of species (e.g., Behbehani, 1995; Bolles
and Fanselow, 1980; Harris, 1996; Millan, 2002; Rodgers, 1995).
According to Bolles and Fanselow (1980), fear and pain are
independent and competing motivational systems implicated in
distinct biological functions. In this context, besides inducing
defensive reactions, systemic or intracerebroventricular injections of
CRF also elicit antinociception (e.g., Bogdanov and Yarushkina, 2007;
Lariviere and Melzack, 2000). However, it remains unknown whether
CRF1 or CRF2 receptors located within the midbrain PAG play a role in
the antinociceptive effect of CRF.
In the present study, we investigated the role played by CRF1 and
CRF2 receptors located within the mouse PAG on the anxiogenic and
antinociceptive effects produced by local infusion of CRF. To block CRF
receptors, we used the selective CRF1 and CRF2 receptor antago-
nists, respectively, NBI 27914 ((5-chloro-4-(N-cyclopropyl)methyl-
N-propyl)-2-methyl-6-(2,4,6-trichlorophenyl) aminopyridine)
(Hammack et al., 2003; Jochman et al., 2005), and antisauvagine-30
(Sahuque et al., 2006; Takahashi et al., 2001).
2. Materials and methods
2.1. Subjects
Subjects were 101 male adult Swiss mice (Univ. Estadual Paulista—
UNESP, SP, Brazil) weighing 25–35 g at testing. Mice were housed in
groups of 10 per cage (size: 41×34×16 cm) and maintained under a
normal 12-h light cycle (lights on at 7:00 am) in a temperature- and
humidity-controlled environment (23±2 °C/R.H. 55±5%). Food and
waterwere freely available except during the brief test periods. Allmice
were naïve at the beginning of the experiments.
2.2. Drugs
Drugs used were: corticotropin-releasing factor (CRF — 75 and
150 pmol; Sigma-Aldrich, Brazil); NBI 27914 [5-chloro-4-(N-
cyclopropyl)methyl-N-propyl)-2-methyl-6-(2,4,6-trichlorophenyl)
aminopyridine], a selective CRF1 receptor antagonist (2 nmol; Tocris
Cookson Inc., Ballwin, USA); antisauvagine 30, a selective CRF2antagonist (1 nmol; Tocris Cookson Inc., Ballwin, USA). The doses used
were based on previous studies (Hammack et al., 2003; Jochman et al.,
2005; Martins et al., 1997; Risbrough et al., 2003; Sahuque et al., 2006,
Takahashi et al., 2001). NBI was dissolved in dimethylsulfoxide (80%
DMSO in physiological saline). CRF and antisauvagine-30 were
dissolved in physiological saline (0.9% NaCl).
2.3. Surgery and microinjection
Stainless steel guide cannulae (7 mm long, 26-gauge; Insight
Equipamentos Cientíﬁcos Ltd., Brazil) were implanted in mice
anesthetized by intraperitoneal injection of ketamine (80 mg/kg)
plus xylasin (8 mg/kg). The guide cannula was ﬁxed to the skull with
dental acrylic and jeweler's screws. Stereotaxic coordinates (Paxinos
and Fraklin, 2001) for the PAGwere, respectively, 4.1 mm posterior to
bregma, 1.3 mm lateral to themidline, and 2.2 mm ventral to the skull
surface, the guide cannula being angled at 26° to the vertical. A
dummy cannula (33-gauge stainless steel wire; Fishtex Industry and
Commerce of Plastics Ltd.), inserted into the guide cannula immedi-
ately after surgery, served to reduce the incidence of occlusion.
Five to seven days after surgery, the various solutions were
injected into the PAG through microinjection units (33-gauge
stainless steel cannula; Insight Equipamentos Cientíﬁcos Ltd., Brazil),
which extended 1.0 mm beyond the tip of the guide cannula. Each
microinjection unit was attached to a 5-μl Hamilton microsyringe via
polyethylene tubing (PE-10), and drug administration was controlled
by an infusion pump (BI 2000, Insight Equipamentos Cientíﬁcos Ltd.,
Brazil) programmed to deliver 0.2 μl over a period of 60 s. The
microinjection procedure consisted of gently restraining the animal,
removing the dummy cannula, inserting the injection unit which
remained in situ for a further 60 s, following the injection.
Conﬁrmation of successful infusion was obtained by monitoring the
movement of a small air bubble in the PE-10 tubing.
2.4. Elevated plus maze and behavioral analysis
The basic EPM design was very similar to that originally described
by Lister (1987) and comprised two open arms (30×5×0.25 cm) and
two closed arms (30×5×15 cm) connected via a common central
platform (5×5 cm). The apparatus was constructed from wood
(ﬂoor) and transparent glass (clear walls) and was raised to a height
of 38.5 cm above ﬂoor level.
After each drug treatment (see Section 2.6 General procedure) in
the PAG (Fig. 1), each mouse was placed in an individual holding cage
and then transported to the maze. Testing commenced by placing the
subject on the central platform of themaze (facing an open arm), after
which the experimenter immediately withdrew to an adjacent
laboratory. The videotaped test sessions were 5 min in duration and,
between subjects, the maze was thoroughly cleaned with 20% alcohol.
All experiments were performed under normal laboratory illumina-
tion (1×60 W yellow incandescent lamp positioned approximately
1.80 m above the EPM ﬂoor), during the light phase of the light–dark
cycle.
Videotapes were scored by a highly trained observer using an
ethological analysis package developed by Dr. Morato's group at
Faculdade de Filosoﬁa, Ciências e Letras de Ribeirão Preto, University
of São Paulo (personal communication). Behavioral parameters
comprised both conventional spatiotemporal (Experiments 1–3)
and ethological (Experiments 2 and 3) measures (Rodgers and
Johnson, 1995). Conventional measures were the frequencies of
closed arm entries (arm entry=all four paws into an arm), percent
open entries [(open/total)×100)], and percent spent in open arms of
the maze [e.g., (time open/300)×100]. Ethological measures com-
prised frequency scores for open arm end exploration (OAEE: entering
the open arm 10-cm distal section from the central square), head
dipping (HD: exploratory movement of head/shoulders over the side
AB
Fig. 1. (A) A schematic representation of microinfusion sites within the midbrain dorsal periaqueductal gray (dPAG) of the mouse. Black circle corresponds to whole area in which
the various microinjections were placed in each slice (distance from bregma in mm), taken from the Paxinos and Fraklin (2001) Atlas. (B) Photomicrograph of midbrain coronal
section from a representative subject, showing an injection site into the dPAG. Section corresponds to −4.24 mm from bregma in the atlas of Paxinos and Fraklin (2001).
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in which the body stretched forward then retracted to the original
position without any forward locomotion). In view of importance of
thigmotactic cues to patterns of plus-maze exploration (Treit et al.,
1993) head dipping and SAP were further differentiated as a function
of whereabouts on the maze they were displayed. Consistent with
earlier reports (Rodgers and Johnson, 1995) the closed arms and the
central platform were together designated “protected” areas (i.e.,
offering relative security), while the open arms were designated
“unprotected” areas. Data for the HD and SAP measures are reported
both as protected and unprotected scores.
2.5. Nociception analysis
Nociception was assessed by the formalin test as previously
described (Abbott et al., 1995). The formalin test causes a two-phase
nociceptive response (Dubuisson and Dennis, 1977). The ﬁrst phase
begins immediately after formalin injection and lasts approximately
5 min. It results from the direct stimulation of nociceptors (Dubuisson
and Dennis, 1977; McCall et al., 1996). The second phase begins
20 min after the injection and lasts approximately 40 min (Bon et al.,
2002). In the present study, 50 μl of formalin (2.5%) was injected into
the dorsal surface of the right hind paw of the mouse, which was
placed in a glass holding cage (30 cm×20 cm×25 cm). Nociceptive
response was recorded by measuring the time (in seconds) spent on
licking the paw injected with formalin.2.6. General procedure
2.6.1. Experiment 1: Effects of intra-PAG injection of CRF on anxiety-like
indices and nociception
2.6.1.1. Anxiety test. Five to six days after surgery, mice were
transported to the experimental room and left undisturbed for at
least 30 min prior to testing (this procedure was followed in all three
experiments). Each mouse then received a microinjection (0, 75 or
150 pmol) of CRF in the PAG and 10 min later it was placed on the
EPM and conventional spatiotemporal measures (see Section 2.4
above) were recorded for 5 min.
2.6.1.2. Nociception test. Formalin was injected into the hind paw of
mice 48 h after the EPM test and 25 min later they received an intra-
PAG injection of CRF (0, 75 or 150 pmol) and placed in the glass
holding cage for 10 min to record the time spent on licking the
injected paw (25–35 min after formalin injection).
2.6.2. Experiment 2: Effects of combined intra-PAG injections with NBI
27914, a CRF1 receptor antagonist, and CRF on anxiety-like indices and
nociception
2.6.2.1. Anxiety test. NBI 27914 (0 or 2 nmol) was microinjected into
the PAG of the mice (pretreatment) and 10 min later they received a
(0 or 150 pmol) microinjection of CRF into the PAG (treatment). After
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both conventional spatiotemporal and ethological measures (see
Section 2.4 above) for a period of 5 min.
2.6.2.2. Nociception test. Formalin was injected into the hind paw of the
mice, 48 h after the EPM test, and 5 min later they received an intra-PAG
injection of NBI 27914 (pretreatment; 0 or 2 nmol) and, 10 min later, an
injection of CRF (treatment; 0 or 150 pmol). Ten minutes later, mice
were individually placed in the glass holding cage for 10 min, to record
the time spent on licking the injected paw (25–35 min after formalin
injection).
2.6.3. Experiment 3: Effects of combined intra-PAG injections with
antisauvagine 30 (ASV 30), a CRF2 receptor antagonist, and CRF on
anxiety-like indices and nociception
2.6.3.1. Anxiety test. Mice received a microinjection of ASV 30 (0 or
1 nmol) into the PAG (pretreatment) and 10 min later they received a
CRF (0 or 150 pmol) microinjection into the PAG (treatment). After
10 min, each mouse was placed on the EPM, to record both
conventional spatiotemporal and ethological measures (see Section
2.4 above) for a period of ﬁve minutes.0
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Fig. 2. (A) Effects of CRF microinjection (0, 75 or 150 pmol) into the dPAG upon
frequency of closed arm (CA) entries (upper panel) as well as on percent of open-arm
entries and percent of open-arm time (lower panel) in the EPM. Bars represent means
(± SEM). N=9–15. *pb0.05 compared to vehicle group. (B) Effects of CRF
microinjection (0, 75 or 150 pmol) into the dPAG on time (in seconds) spent on
licking the formalin injected paw in mice. Bars represent means (± SEM). N=8–13.
*pb0.05 compared to vehicle group.2.6.3.2. Nociception test. Formalin was injected into the hind paw of
the mice, 48 h after the EPM test, and 5 min later they received an
intra-PAG injection of ASV 30 (pretreatment; 0 or 1 nmol) and,
10 min later, an injection of CRF (treatment; 0 or 150 pmol). Ten
minutes later, mice were individually placed in the glass holding
cage for 10 min, to record the time spent on licking the injected paw
(25–35 min after formalin injection).
Importantly, all animals of Experiments 1–3 that had received
intra-dPAG injection of CRF on day 1 (EPM test) received saline on day
3 (Nociception test) and vice versa.
2.7. Histological analysis
At the end of testing, all animals received a 0.1 μl intra-PAG
infusion of 1% Evans blue by the same microinjection procedure as for
the drugs. Animals were then sacriﬁced by anesthetic overdose, their
brains removed and injection sites checked histologically by reference
to the atlas of Paxinos and Fraklin (2001). Data from animals with
injection sites outside the PAG were excluded from the study.
2.8. Statistical analysis
All results were initially submitted to Levene's test for homoge-
neity of variance. Where Levene's test yielded signiﬁcant heteroge-
neity, results were transformed to the log, square root or cube root
and then conﬁrmed for homogeneity of variance before being
subjected to one- or two-way analysis of variance (ANOVA). Finally,
data were subjected to the post hoc Duncan test. In Experiment 1,
one-way ANOVA was carried out. In Experiments 2 and 3, two-way
ANOVA was carried out (factor 1, pretreatment; factor 2, treatment).
In all cases, a P value≤0.05 was required for signiﬁcance.
2.9. Ethics
The experimental protocols were conducted according to the
ethical principles of the Brazilian College of Animal Experimentation
(COBEA) and approved by the local Research Ethics Committee (CEP/
FCF/Car-UNESP: protocol number 10/2006).
3. Results
3.1. Brain injection site
Fig. 1 shows a schematic representation of microinfusion sites
within the midbrain dorsal periaqueductal gray (dPAG) and a
photomicrograph of a midbrain coronal section of a representative
subject, showing an injection site into the dPAG of the mouse.
3.2. Experiment 1: Effects of intra-dPAG injection of CRF on anxiety-like
indices and nociception
Fig. 2A shows the frequency of closed arm entries and anxiety-like
indices recorded for a 5-min period in the EPM in mice microinjected
with CRF (0, 75 or 150 pmol) into the dPAG. One-way ANOVA
followed by Duncan test revealed that CRF (150 pmol) decreased the
percentage of open-arm entries (F2,34=5.38; pb0.05) and percentage
of open-arm time (F2,34=7.03; pb0.05). In addition, one-way ANOVA
revealed signiﬁcant differences in closed-arm entries (F2,34=3.29;
pb0.05) and the post-hoc test showed that CRF (75 pmol) decreased
the closed-arm entries.
Fig. 2B shows the time spent on licking the paw injected with 2.5%
formalin in mice treated with CRF (0, 75 or 150 pmol) into the dPAG.
One-way ANOVA revealed signiﬁcant differences between groups
(F2,28=9.2; pb0.05) and post-hoc comparisons (Duncan's test)
revealed that CRF (150 pmol) decreased the time spent on licking
the paw injected with formalin.
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Fig. 3. Effects of combined intra-dPAG microinjections of NBI 27914 (0 or 2 nmol) and CRF (0 or 150 pmol) on the (A) spatiotemporal measures [frequency of closed-arm (CA)
entries (upper panel), percent of open-arm entries and percent of open-arm time (lower panel)] and (B) ethological measures [frequency of protected and unprotected stretched-
attend postures (SAP), protected and unprotected head dipping (HD), and open arm end exploration (OAEE)] in mice exposed to the EPM. Bars represent means (± SEM). N=9–14.
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27914 and CRF on anxiety-like indices and nociception
Fig. 3A shows the effects of combined injections of NBI 27914 (0 or
2 nmol) and CRF (0 or 150 pmol) into the PAG on the behavior of mice
exposed in the EPM. Two-way ANOVA revealed signiﬁcant differences
for the NBI 27914 and CRF treatments on% open-arm entries (NBI:
F1,37=4.22; pb0.05; CRF: F1,37=15.16; pb0.05) and% open-arm time
(NBI: F1,37=4.06; pb0.05; CRF: F1,37=9.84; pb0.05), but did not
reveal a signiﬁcant effect for the NBI×CRF interaction on either index
(% open arm entries: F1,37=1.06; p=0.31;% open arm time:
F1,37=0.98; p=0.33). Post-hoc comparisons conﬁrmed the results
of Exp. 1, demonstrating that CRF decreased the% open-arm entries
and% open-arm time (pb0.05), compared to control (veh+veh).
Duncan's test also revealed that the NBI 27914 injection selectively
blocked the CRF effects on both anxiety indices. Also, ANOVA did notreveal any effect for the NBI (F1,37=0.13; p=0.72) and CRF
(F1,37=0.16; p=0.69) treatments or NBI versus CRF interactions
(F1,37=0.39; p=0.54) on closed-arm entries (Fig. 3A).
Consistent with the above observations, analysis also revealed
some signiﬁcant changes in the ethological measures, namely
protected SAP (CRF: F1,37=6.86, pb0.05; NBI x CRF interaction:
F1,37=4.82, pb0.05), unprotected SAP (NBI: F1,37=4.47, pb0.05;
CRF: F1,37=11.73, pb0.01), unprotected HD (NBI: F1,37=5.01,
pb0.05; CRF: F1,37=18.24, pb0.01); OAEE (CRF: F1,37=8.79,
pb0.01) (Fig. 3B). Post-hoc comparisons indicated that, relative to
the veh+veh control group, veh+CRF increased protected SAP
(pb0.01) and decreased unprotected SAP (pb0.01), unprotected HD
(pb0.01) and OAEE (pb0.05). Interestingly, post-hoc Duncan test
revealed that the NBI+CRF group decreased the effects produced by
CRF (veh+CRF) on protected and unprotected SAP (pb0.05). Also,
NBI+CRF group tended to reduce CRF effects on unprotected HD
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signiﬁcantly affected by any of the treatments (F1,37=2.72,
p=0.11) (Fig. 3B).
Fig. 4 shows the effects of combined injections of NBI 27914 (0 or
2 nmol) and CRF (0 or 150 pmol) into the dPAG on the time spent on
licking 2.5% formalin-injected paw. Two-way ANOVA did not reveal
any differences for the NBI 27914 treatment (F1,32=2.49; p=0.12),
but showed signiﬁcant differences for the CRF treatment
(F1,32=10.45; pb0.05) and a tendency toward an effect for the NBI
versus CRF interaction (F1,32=3.51; p=0.07). Post-hoc comparisons
revealed that CRF (veh+CRF) reduced the time spent on licking
the injected paw, compared to the control group (veh+veh).
However, intra-dPAG NBI 27914 blocked the antinociceptive effect
of CRF (NBI+CRF vs veh+CRF; pb0.05)without provoking any effect
alone (NBI+veh vs veh+veh; p=0.83).3.4. Experiment 3: Effects of combined intra-dPAG injections of
antisauvagine 30 (ASV 30), a CRF2 receptor antagonist, and CRF on
anxiety-like indices and nociception
Fig. 5A shows the effects of combined injections of ASV 30 (0 or
1 nmol) and CRF (0 or 150 pmol) into the dPAG on the behavior of
mice exposed in the EPM. Two-way ANOVA did not reveal any
signiﬁcant difference for the ASV 30 treatment on% open-arm entries
(F1,42=0.02; p=0.89) or% open-arm time (F1,42=0.09; p=0.77),
but showed a signiﬁcant effect for the CRF treatment on both indices
(% open-arm entries: F1,42=26.48; pb0.05;% open-arm time:
F1,42=28.65; pb0.05). No effect of ASV 30×CRF interaction were
revealed on either anxiety index (% open-arm entries: F1,42=0.05,
p=0.82;% open-arm time: F1,42=0.08; p=0.78). Post-hoc compar-
isons conﬁrmed the CRF effects in decreasing% open-arm entries and%
open-arm time (pb0.05), compared to control (veh+veh), and
revealed that ASV 30 did not change the CRF effects in either anxiety-
like index. Also, ANOVA did not reveal any effect for the ASV 30
pretreatment (F1,42=0.26; p=0.61), CRF treatment (F1,42=2.47;
p=0.12) or ASV 30 versus CRF interaction (F1,42=0.35; p=0.56) on
closed-arm entries (Fig. 5A).
As shown in Fig. 5B, ANOVA also revealed some signiﬁcant effects
for CRF treatment in the ethological measures (protected SAP:
F1,42=20.59, pb0.01; unprotected SAP: F1,42=16.88, pb0.01; unpro-
tected HD: F1,42=20.56, pb0.01; OAEE: F1,42=14.18, pb0.01). Post-
hoc comparisons conﬁrmed that both veh+CRF and ASV 30+CRF
groups showed higher frequency in protected SAP (pb0.01) and
lower frequency in unprotected SAP (pb0.05), unprotected HD
(pb0.01) and OAEE (p≤0.05) compared to veh+veh control group.0
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Fig. 4. Effects of combined intra-dPAG microinjections of NBI 27914 (0 or 2 nmol) and
CRF (0 or 150 pmol) on the time (in seconds) spent on licking the formalin-injected
paw. Bars represent means (± SEM). N=8–11. *,#pb0.05 compared to control group
(veh+veh) and to veh+CRF group, respectively.Protected HD was not signiﬁcantly affected by any of the treatments
(F1,42≤0.50, p=0.48) (Fig. 5B).
Fig. 6 shows the effects of combined injections of ASV 30 (0 or
1 nmol) and CRF (0 or 150 pmol) into the PAG on time spent on
licking the 2.5% formalin-injected paw. Two-way ANOVA did not
reveal signiﬁcant differences for the ASV 30 treatment (F1,33=1.49;
p=0.23) or for the ASV 30×CRF interaction (F1,33=0.05; p=0.83),
but showed signiﬁcant differences for the CRF treatment (F1,33=
33.34; pb0.05). Post-hoc comparisons revealed that CRF (veh+CRF)
reduced the time spent licking the formalin-injected paw, compared
to the control group (veh+veh), an effect that was not blocked by
intra-dPAG pretreatment with ASV 30.
4. Discussion
The main results of the present study showed that intra-dPAG
injections of CRF enhanced anxiety-like behavior in the EPM and
inhibited the nociceptive response induced by formalin injection into
the paw in mice. In addition, prior intra-dPAG injections of CRF1 (but
not CRF2) receptor antagonist attenuated both the anxiogenic and
antinociceptive effects produced by CRF injection into this limbic
midbrain structure.
Intra-dPAG microinjections of CRF reduced open arm exploration
without affecting general activity (closed-arm entries) in the EPM.
This result corroborates previous studies demonstrating that intra-
PAG CRF enhances anxiety-like indices in the EPM in rats (Borelli and
Brandão, 2008; Martins et al., 1997) as well as in mouse anxiety tests
such as the mouse defense test battery (MDTB) and rat exposure test
(RET, Carvalho-Netto et al., 2007). Here, the anxiogenic effects of CRF
(i.e., reduction in% open-arm entries and% open-arm time) were
completely blocked by a prior intra-dPAG injection of NBI 27914, a
CRF1 receptor antagonist. Importantly, closed-arm entries, a widely
used measure of general activity level (e.g., Cruz et al., 1994; Rodgers
and Johnson, 1995), remained unchanged in animals treated with NBI
27914, combined either with CRF or with vehicle, suggesting that the
NBI 27914 effects were selective in reducing the anxiogenic effects
produced by CRF. The reduction in the closed-arm entries observed
with the lower dose of CRF (Fig. 2A) seems to be an isolated effect,
since the higher dose of the neuropeptide did not conﬁrm this effect,
either when injected alone (Fig. 2A) or combined with vehicle
(Figs. 3A and 5A). Indeed, in addition to preventing the anxiogenic-
like effects of intra-dPAG CRF on direct measures of open arm
exploration (see above), intra-dPAG NBI 27914 also prevented the
anxiogenic-like increase in protected SAP and reduction in unpro-
tected SAP as well as tended to reduce unprotected HD and open arm
end exploration seen in response to CRF treatment. Importantly, intra-
dPAG NBI 27914 was completely devoid of intrinsic behavioral
activity under present test conditions. Taken together, the present
results suggest that the antianxiety effect following deletion of CRF1
receptor gene in mice observed elsewhere (Contarino et al., 1999;
Smith et al., 1998; Timpl et al., 1998) might be at least in part due to a
dysfunction of PAG CRF1 receptor activity.
Intra-dPAG injections of CRF also reduced the nociceptive response
induced by formalin injection into the hind paw. CRF-treated animals
showed a reduction in the time spent on licking the formalin-injected
paw, characterizing an antinociceptive role played by this neuropep-
tide in the mouse PAG. Presently, we do not know how CRF elicits
antinociception in the PAG. Possibly, CRF activates neurons that
belong to the descending inhibitory system of pain (Fields and
Basbaum, 1999), which, in turn, inhibit nociceptive afferents in the
dorsal horn of the spinal cord (Harris, 1996; Kharkevich and
Churukanov, 1999; Millan, 2002). Similar to what was observed in
anxiety-like indices, intra-dPAG injection of NBI 27914 completely
blocked the antinociceptive effect of CRF, suggesting, for the ﬁrst time,
that CRF1 receptors located within this midbrain structure play a role
in the modulation of nociception.
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to be selective for the CRF1 receptor, since intra-dPAG microinjection
of ASV 30, a CRF2 receptor antagonist, altered neither the anxiety nor
the antinociception response. Intra-dPAG ASV 30 was also unable to
prevent the anxiogenic (observed in both conventional and etholog-
ical anxiety-related measures) and antinociceptive effects produced
by local infusion of CRF. Thus, despite their presence in all columns of
the PAG (Steckler and Holsboer, 1999), CRF2 receptors do not play a
role in anxiety, assessed in the EPM, or in nociception assessed in the
formalin test in mice.
Regarding the effects of CRF on anxiety, Sahuque et al. (2006) have
demonstrated that this neuropeptide also enhances anxiety when
injected into the bed nucleus of the stria terminalis (BNST), a brain
structure that has also been related to defensive behavior (Casada and
Dafny, 1991; Chen et al., 2009;Walker et al., 2003). Those authors also
demonstrated that intra-BNST injections of a CRF1 (but not CRF2)
receptor antagonist prevented the anxiogenic effect produced by CRF.Importantly, Sahuque et al. (2006) demonstrated that intra-BNST ASV
30, at the same dose employed in the present study, was able to
prevent place aversion induced by local CRF injection, but did not
attenuate the anxiogenic effect produced by this neuropeptide in rats
exposed to the EPM. In view of these ﬁndings, it seems that the
emotional state elicited by EPM exposure does not recruit CRF2
receptors located within the BNST (Sahuque et al., 2006) and dPAG
(present results) in rats and mice, respectively.
It has been demonstrated that CRF has a higher afﬁnity for CRF1
receptors than for CRF2 receptors (Vaughan et al., 1995). This
differential afﬁnity might be the main reason for the presently
observed lack of effect of ASV 30 on the anxiogenic and antinocicep-
tive effects produced by CRF. However, it has been reported that the
anxiogenic-like effects produced with i.c.v. injections of CRF
(200 pmol) in mice exposed to the startle paradigm were attenuated
with i.c.v. injection of ASV 30 (Risbrough et al., 2003), at a similar dose
to that used in the present study. Therefore, it is likely that the dose of
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(0 or 150 pmol) on time (in seconds) spent on licking the formalin-injected paw. Bars
represent means (± SEM). N=8–11. *pb0.05 compared to control group (veh+veh).
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sufﬁciently high to activate CRF2 receptors in the present study.
Moreover, while i.c.v. injection of a selective CRF1 receptor agonist,
stressin-1A, produces anxiogenic-like effects in rats exposed to the
shock probe test, no effects were observed with urocortine III, a
selective CRF2 receptor agonist (Zhao et al., 2007). These inconsistent
results indicate a need for further studies with different animal
models of anxiety to better understand the role of CRF2 receptors in
the neurobiology of emotional states. In this context, the present
results indicate that the PAG CRF1 (but not CRF2) receptor is an
important target on which CRF exerts its anxiogenic-like actions in
mice exposed to the EPM.
Finally, it has been emphasized that the PAG receives CRF-containing
neuron projections from other anxiety-related brain structures such as
amygdala, hypothalamus and BNST (Gray and Magnuson, 1992).
Furthermore, studies in vitro have shown an excitatory effect on PAG
neurons following CRF administration (Bowers et al., 2003). Thus, the
CRF anxiogenic and antinociceptive actions observed in the present
study might be associated with a neuron-ﬁring response as a
consequence of membrane depolarization provoked by this neuropep-
tide within the PAG. Although both CRF1 and CRF2 receptors have been
found in the PAG (Merchenthaler, 1984; Swanson et al., 1983), present
results suggest that the anxiogenic and the antinociceptive effects of CRF
introduced into the dPAG are related to CRF1 but not CRF2 receptor
activation. However, given the contrasting effects observed with
manipulation of CRF2 receptors in emotional tests (Bale et al., 2000;
Kishimoto et al., 2000; Radulovic et al., 1999; Risbrough et al., 2003;
Takahashi et al., 2001; Zhao et al., 2007), it is important to point out that
further studies are needed to determine the role played by this CRF
receptor subtype in the nociception response as well as in anxiety-
related behavior.
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